natgillin/translations-raw huggingface dataset:
reacting compound 3 with a reducing agent to form compound 4 as a mixture of 4 and 5 
Reakciju spoja 3 s reducirajućim agensom za dobivanje spoja 4 kao mješavine spoja 4 i 5;
reacting compound 4 with a two carbon olefination reagent under olefin forming conditions to form compound 6 
Reakciju spoja 4 s dvokarbonskim olefinationskim reagensom pod uvjetima u kojima se tvori olefin za dobivanje spoja 6;
converting compound 6 to a compound of formula 7 
Pretvorbu spoja 6 u spoj formule 7;
reacting the compound of formula 10 with H2 under hydrogenation conditions to form a compound of formula 11 wherein P is a protecting group and R is alkyl; 
Reakciju spoja formule 10 s H2 pod hidrogenirajućim uvjetima za dobivanje spoja formule 11 pri čemu je P zaštitna grupa, a R je alkil;
reacting the compound of formula 9 with an oxidizing agent to form a compound of formula 10 wherein P is a protecting group such as acetyl and R is alkyl; 
Reakciju spoja formule 9 s oksidirajućim agensom za dobivanje spoja formule 10 pri čemu je P zaštitna grupa kao primjerice acetil, a R je alkil;
reacting the compound of formula 11 with a reducing agent to form a compound of formula 12 wherein P is a protecting group and R is alkyl; and 
Reakciju spoja formule 11 s reducirajućim agensom za dobivanje spoja formule 12 pri čemu je P zaštitna grupa, a R je alkil;
exposing the compound of formula 12 to deprotection conditions to form an ester thereof and to suitable hydrolysis conditions to form deoxycholic acid or a pharmaceutically acceptable salt thereof. 
Izlaganje spoja formule 12 uvjetima gubitka zaštite te formiranje njegovog estera i odgovarajućim uvjetima hidrolize za dobivanje deoksikolne kiseline ili njene farmaceutski prihvatljive soli.
The method of claim 1, wherein the hydrogenation conditions of part (a) comprises a Pd/C catalyst. 
Metoda iz zahtjeva 1 pri kojoj hidrogenirajući uvjeti pod stavkom a) podrazumijevaju Pd/C katalizator.
The method of claim 1, wherein the acid of part (b) is a mineral acid, such as H2SO4. 
Metoda iz zahtjeva 1 pri kojoj je kiselina pod stavkom b) mineralna kiselina, kao što je H2SO4.
The method of claim 1, wherein the hydrogenation conditions of part (g) comprises a PtO2 or Pd/C catalyst. 
Metoda iz zahtjeva 1 pri kojoj hidrogenirajući uvjeti pod stavkom g) podrazumijevaju PtO2 ili Pd/C katalizator.
The method of claim 1, wherein the hydrogenation conditions of part (i) comprises a Pd/C catalyst. 
Metoda iz zahtjeva 1 pri kojoj hidrogenirajući uvjeti pod stavkom i) podrazumijevaju Pd/C katalizator.
A compound of formula 6 
Spoj formule 6:
A compound of formula 3 
[image] Spoj formule 3:
A compound of formula 8 wherein P is a protecting group such as acetyl. 
Spoj formule 8: [image] Pri čemu je P zaštitna grupa kao što je acetil.
said matrix is impregnated with said polymeric material, or both. 
navedena matrica je impregnirana s navedenim polimernim materijalom, ili oboje.
chitosan, a synthetic biodegradable biomaterial, e.g. 
kitosan, sintetski biorazgradivi biomaterijal, npr.
Use of a sponge of any one of claims 1 to 5 for the manufacture of a medicament for treatment of an injury selected from the group consisting of a wound, a hemorrhage, damaged tissue and/or bleeding tissue. 
Spužva prema bilo kojem od zahtjeva 1 do 5 naznačena time da je za uporabu za liječenje ozljede odabrane iz skupine koju čine rana, krvarenje, ozlijeđeno tkivo i/ili krvarenje tkiva.
an alkaline buffer solution, such as a bicarbonate, together with instructions for its use. 
alkalnu pufersku otopinu, kao što je bikarbonat, zajedno s instrukcijama za njegovu uporabu.
providing a sponge comprising a matrix of a biomaterial in dried form, 
osiguravanja porozne spužve koja sadrži matricu biomaterijala u suhom obliku,
providing a single hydrophilic polymeric component, said component comprising electrophilic reactive groups, wherein said hydrophilic polymeric component is a hydrophilic crosslinker, in the form of dry powder, 
osiguravanja jedne hidrofilne polimerne komponente koja sadrži elektrofilne reaktivne skupine u obliku suhog praška, pri čemu navedeni jedan reaktivni polimerni materijal je hidrofilno sredstvo za umrežavanje,
contacting a) and b) so that the material of b) is present on at least one surface of said sponge,and 
kontaktiranje a) i b) tako da se materijal iz b) nalazi na barem jednoj površini navedene spužve, te
fixing the material of b) on the sponge of a). 
učvršćivanje materijala iz b) na spužvu iz a).
providing a single hydrophilic polymeric component, said component comprising electrophilic reactive groups, wherein said hydrophilic polymeric component is a hydrophilic crosslinker, in the form of a solution, 
osiguravanja jedne hidrofilne polimerne komponente koja sadrži elektrofilne reaktivne skupine u obliku otopine, pri čemu navedeni jedan reaktivni polimerni materijal je hidrofilno sredstvo za umrežavanje,
contacting a) and b) so that the material of a) is impregnated with b), and 
kontaktiranje a) i b) tako da je materijal iz a) impregniran s b), i
drying the material obtained in step c). 
sušenje materijala dobivenog u koraku c).
An activated cytotoxic T lymphocyte (CTL), produced by the method according to Claim 9, which selectively recognises a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in claim 1 or 2. 
Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 9 ili 10, koji selektivno prepoznaje peptid u skladu sa zahtjevom 1 ili 2.
A composition comprising as an active principle a compound consisting of an antibody, or divalent, antigen-binding fragments thereof, as claimed in one of claims 1, 2, and 4-7, or obtained by the method of claim 12 or produced by hybridoma according to claim 3. 
Pripravak koji kao aktivni sastojak sadrži spoj koji se sastoji od antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met kao što je prijavljeno u jednom od patentnih zahtjeva 1, 2 te 4 - 8 ili je dobiven metodom iz patentnog zahtjeva 12, ili je dobiven pomoću hibridoma prema patentnom zahtjevu 3.
The composition of any one of claims 14 to 16, characterized in that it further comprises at least one agent as a combination product for simultaneous, separate or sequential use, wherein said agent is a cytotoxic/cytostatic agent. 
Pripravak iz patentnog zahtjeva 14 ili 15, naznačen time da dalje sadrži najmanje jedno sredstvo kao kombinacijski produkt za istodobnu, odvojenu ili uzastopnu upotrebu, pri čemu rečeno sredstvo jest citotoksično/citostatko sredstvo.
R and R' represent, the same or different from each other, a hydroxyalkylamino group of formula -NHR1 or -NR2R3, wherein R1, R2 and R3 are, the same or different from each other, a straight or branched C1-C6 alkyl group which is optionally substituted by one or more groups selected from hydroxyl (-OH), C1-C5 alkoxy or hydroxyalkoxy groups. 
R i R' predstavljaju, istu ili međusobno različitu, skupinu s formulom -NHR1 ili -NR2R3, pri čemu svaki R1, R2 i R3 je, međusobno neovisno, ravnolančana ili razgranata C1-C6 alkil skupina koja je proizvoljno supstituirana s jednom ili više skupina odabranih iz skupine koju čine hidroksil (-OH), C1-C5 alkoksi ili hidroksialkoksi skupine.
The process of claims 8-9 comprising adding solid I2 to said aqueous solution of 3,5-di-substituted phenol substrate heated to a temperature comprised from 30 to 70°C and then adding iodic acid in a time of up to 4 hours. 
Postupak prema zahtjevima 7-8 naznačen time da sadrži dodavanje krutog I2 u navedenu vodenu otopinu supstrata 3,5-disupstituiranog fenola zagrijanu na temperaturu u rasponu od 20 do 70°C i zatim dodavanje jodne kiseline.
The process of claim 13 wherein both R and R' are a -CONH-CH(CH2OH)2 group, R4 is hydrogen and R5 is methyl group. 
Postupak prema zahtjevu 12 naznačen time da oba R i R' su -NH-CH(CH2OH)2 skupina, R4 je vodik i R5 je metil skupina.
System for receiving digital signals comprising a QAM demodulator, characterized in that it is adapted to implement the method according to any one of claims 6 to 8. 
Sustav za primanje digitalnih signala koji sadrži QAM demodulator, naznačen time, da je prilagođen za primjenu postupka u skladu s bilo kojim od patentnih zahtjeva 6 do 8.
System according to claim 9, comprising an audio/video digital signal receiver for digital terrestrial television broadcast signals. 
Sustav u skladu s patentnim zahtjevom 9, naznačen time, da sadržava audio/video digitalni signalni prijamnik za emitiranje digitalnih zemaljskih televizijskih signala.
An anchor shackle (7, 28) for an anchor, the anchor shackle (7, 28) having a longitudinal axis and comprising: 
Škopac za sidro (7, 28), škopac za sidro (7, 28) koji ima uzdužnu os i obuhvaća:
a keyed portion cooperable with a chasing collar (17) to inhibit rotational movement of the anchor shackle (7, 28) around the longitudinal axis when in a locking position within the collar (17), characterised in that the anchor shackle (7, 28) comprises a curved surface curved around the longitudinal axis to facilitate rotational movement of the anchor shackle around the longitudinal axis to the locking position. 
nazubljeni dio koji može zajedno djelovati s prstenom prolaznika (17) kako bi se spriječilo zakretanje škopca za sidro (7, 28) oko uzdužne osi, kada je u položaju za zaključavanje unutar prstena (17), naznačen time, da škopac za sidro (7, 28) ima zaobljenu površinu oko uzdužne osi kako bi se omogućilo zakretno gibanje škopca za sidro oko uzdužne osi u položaj za zaključavanje.
An anchor shackle (7, 28) as claimed in claim 1, wherein the keyed portion comprises a protuberance (18) defined by two faces inclined at an angle relative to each other. 
Škopac za sidro (7, 28) u skladu s patentnim zahtjevom 1, naznačen time, da nazubljeni dio ima izbočinu (18) koju definiraju dvije stranice nagnute jedna prema drugoj pod kutom.
An anchor (3) according to claim 5 when dependent on one of claims 2-4, the anchor (3) having a centre of gravity displaced from the centre of the anchor shackle (7, 28) in the direction of the protuberance (18). 
Sidro (3) u skladu s patentnim zahtjevom 5 kada je ovisan o jednom od patentnih zahtjeva 2 do 4, naznačeno time, da je težište sidra (3) pomaknuto od centra škopca za sidro (7, 28) prema izbočini (18).
An anchor positioning system (1), comprising: 
Sustav za pozicioniranje sidra (1), naznačen time, da obuhvaća:
A system (1) according claim 8, comprising an anchor (3) which comprises the anchor shackle (7, 28), wherein the anchor has a weight distribution arranged to bias the anchor shackle to rotate from the unlocked position to the locked position. 
Sustav (1) u skladu s patentnim zahtjevom 8 koji obuhvaća sidro (3) i škopac za sidro (7, 28), naznačen time, da je raspodjela težine sidra uređena na način da pomiče škopac za sidro na zakretanje iz otključanog položaja u zaključani položaj.
A system (1) according to claim 8 or claim 9, further comprising an anchor body (9) pivotally mounted to the anchor shackle (7, 28). 
Sustav (1) u skladu s patentnim zahtjevom 8 ili patentnim zahtjevom 9, naznačen time, da dodatno obuhvaća tijelo sidra (9), zglobno pričvršćeno na škopac za sidro (7, 28).
A system (1) according to claim 10, wherein pivotal movement of the anchor body (9) is limited to ensure that the anchor has a centre of gravity displaced from the centre of the anchor shackle in the direction of the protuberance (18). 
Sustav (1) u skladu s patentnim zahtjevom 10, naznačen time, da je zakretni pomak tijela sidra (9) ograničen kako bi se osiguralo da je težište sidra pomaknuto od središta škopca za sidro u smjeru izbočine (18).
A system according to any one of claims 9 to 11, wherein the anchor (3) has a centre of gravity displaced from the centre of the anchor shackle (7, 28) in the direction of the protuberance (18). 
Sustav u skladu s bilo kojim od patentnih zahtjeva 9 do 11, naznačen time, da je težište sidra (3) pomaknuto od središta škopca za sidro (7, 28) u smjeru izbočine (18).
a fusion protein comprising first and second peptide portions wherein said first peptide portion consists of an amino acid sequence selected from: wild type B7-DC, an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1 and which competes in vitro with wild-type B7-DC for binding to PD-1, a fragment of B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1, and an extracellular domain of B7-DC and said second peptide portion comprises a portion of an immunoglobulin (Ig); 
fuzijski protein koji sadrži prve i druge dijelove peptida pri čemu navedeni dio prvog peptida sadrži sekvencu aminokiseline odabranu od: divljeg tipa B7-DC, sekvence aminokiseline koja ima najmanje 98% identičnosti sa aminokiselinama 20-221 ili 20-121 iz SEQ ID NO: 1 i koji konkurira in vitro s divljim tipom B7-DC oko vezivanja na PD-1, fragmenta B7-DC koji konkurira in vitro s divljim tipom B7-DC oko vezivanja na PD-1, te izvan staničnu domenu od B7-DC i navedeni dio drugog peptida sadrži dio imunoglobulina (Ig);
for use in a method of increasing a T cell response in a human; 
za uporabu u postupku povećavanja odgovora T stanica kod čovjeka;
A composition comprising a potentiating agent selected from the group consisting of: cyclophosphamide, an analog of cyclophosphamide, sunitinib, anti-TGFβ, imatinib, anthracyclines, oxaliplatin and doxorubicin, for use in a method of increasing a T cell response in a human; 
Pripravak koji sadrži sredstvo za pojačavanje koje je odabrano iz skupa koji sadrži: ciklofosfamid, analog ciklofosfamida, sunitinib, anti-TGFβ, imatinib, antracikline, oksaliplatin i doksorubicin, za uporabu u postupku povećanja odgovora T stanica kod čovjeka;
wherein the human is one to whom a composition comprising a fusion protein comprising first and second peptide portions wherein said first peptide portion consists of an amino acid sequence selected from: wild type B7-DC, an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1 and which competes in vitro with wild-type B7-DC for binding to PD-1, a fragment of B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1, and an extracellular domain of B7-DC and said second peptide portion comprises a portion of an immunoglobulin (Ig), is subsequently to be administered; 
pri čemu čovjek je onaj kojemu se naknadno treba dati pripravak koji sadrži koji sadrži fuzijski protein koji sadrži dijelove prvog i drugog peptida pri čemu navedeni dio prvog peptida sadrži sekvencu aminokiseline odabranu od: divljeg tipa B7-DC, sekvence aminokiseline koja ima najmanje 98% identičnosti sa aminokiselinama 20-221 ili 20-121 iz SEQ ID NO: 1 i koji konkurira in vitro s divljim tipom B7-DC oko vezivanja na PD-1, fragment B7-DC koji konkurira in vitro s divljim tipom B7-DC oko vezivanja na PD-1, te izvan staničnu domenu od B7-DC i navedeni dio drugog peptida sadrži dio imunoglobulina (Ig),;
A composition for use according to claim 1 or 2 wherein said first peptide portion consists of a wild type B7-DC polypeptide. 
Pripravak za uporabu prema zahtjevu 1 ili 2 naznačen time da navedeni dio prvog peptida sadrži divlji tip polipeptida B7-DC.
A composition for use according to claim 1 or 2 wherein said first peptide portion consists of an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1. 
Pripravak za uporabu prema zahtjevu 1 ili 2 naznačen time da navedeni dio prvog peptida sadrži sekvencu aminokiseline koja ima najmanje 98% identičnosti s aminokiselinama 20-221 ili 20-121 iz SEQ ID NO: 1.
A composition for use according to claim 1 or 2 wherein said fusion protein comprises an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 9, 10, 12 or 13. 
Pripravak za uporabu prema zahtjevu 1 ili 2 naznačen time da navedeni fuzijski protein sadrži sekvencu aminokiseline koja ima najmanje 95% identičnosti sa sekvencom iz SEQ ID NO: 9, 10, 12 ili 13.
A composition for use according to any preceding claim for use in a method of any preceding claim wherein said potentiating agent is administered at least X hours before administering said fusion protein, wherein X is selected from 1, 2, 3, 5, 10, 15, 20, 24 and 30. 
Pripravak za uporabu prema bilo kojem prethodnom zahtjevu naznačen time da je za uporabu u postupku prema bilo kojem prethodnom zahtjevu pri čemu se navedeno sredstvo za pojačavanje daje najmanje X sati prije davanja navedenog fuzijskog proteina, pri čemu je X odabran od 1, 2, 3, 5, 10, 15, 20, 24 i 30.
A composition for use according to claim 23 for use in said method wherein said method further comprises administering at least one additional agent selected from the group consisting of an anti-PD-1 antibody, an anti-CTLA4 antibody, a mitosis inhibitor, an aromatase inhibitor, an A2AR antagonist, and an angiogenesis inhibitor with said fusion protein. A kit-of-parts comprising: 
Pripravak za uporabu prema zahtjevu 23 naznačen time da je za uporabu u navedenom postupku pri čemu navedeni postupak dodatno obuhvaća davanje najmanje jednog dodatnog sredstva koje je koje je odabrano iz skupine koja sadrži anti-PD-1 protutijelo, anti-CTLA4 protutijelo, inhibitor mitoze, inhibitor aromataze, antagonist A2AR, te inhibitor angiogeneze s navedenim fuzijskim proteinom.
for use in a method of treating cancer; 
naznačen time da je za uporabu u postupku liječenja raka;
wherein said cyclophosphamide is administered before said fusion protein and said fusion protein is administered without cyclophosphamide following administration of cyclophosphamide; 
pri čemu se navedeni ciklofosfamid se daje prije navedenog fuzijskog proteina i navedeni fuzijski protein se daje bez ciklofosfamida nakon davanja ciklofosfamida;
The composition for use according to claim 27 for use in the method of claim 27 wherein said cyclophosphamide is administered to said patient at least 24 hours prior to the administration of the fusion protein. 
Pripravak za uporabu prema zahtjevu 27 naznačen time da je za uporabu u postupku prema zahtjevu 27 pri čemu se navedeni ciklofosfamid daje navedenom pacijentu najmanje 24 sata prije davanja fuzijskog proteina.
A kit of parts comprising: 
Komplet (kit) dijelova koji sadrži:
a fusion protein comprising first and second peptide portions wherein said first peptide portion consists of an amino acid sequence selected from: wild type B7-DC, an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1 and which competes in vitro with wild-type B7-DC for binding to PD-1, a fragment of B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1, and an extracellular domain of B7-DC and said second peptide portion comprises a portion of an immunoglobulin (Ig); 
fuzijski protein koji sadrži dijelove prvog i drugog peptida pri čemu navedeni dio prvog peptida sadrži sekvencu aminokiseline odabranu od: divljeg tipa B7-DC, sekvence aminokiseline koja ima najmanje 98% identičnosti s aminokiselinama 20-221 ili 20-121 iz SEQ ID NO: 1 i koja se natječe in vitro s divljim tipom B7-DC oko vezivanja na PD-1, fragment B7-DC koji se natječe in vitro s divljim tipom B7-DC oko vezivanja na PD-1, te izvan stanične domene B7-DC i navedeni dio drugog peptida obuhvaća dio imunoglobulina (Ig);
and a potentiating agent selected from the group consisting of: cyclophosphamide, an analog of cyclophosphamide, sunitinib, anti-TGFβ, imatinib, anthracyclines, oxaliplatin and doxorubicin; 
i sredstvo za pojačavanje koje je odabrano iz skupine koja sadrži: ciklofosfamid, analog ciklofosfamida, sunitinib, anti-TGFβ, imatinib, antracikline, oksaliplatin i doksorubicin;
for use in a method of increasing a T cell response in a human; 
naznačen time da je za uporabu u postupku povećanja odgovora T stanica kod čovjeka;
and instructions for employing said probe to identify patients likely to develop peripheral neuropathy in response to treatment for cancer. 
i upute za korištenje navedene sonde za identificiranje pacijenata koji će vjerojatno razviti perifernu neuropatiju kao odgovor na liječenje raka.
or 2 copies of the minor allele, T, of rs1261134, wherein the presence of said biomarker indicates an increased risk for said adverse neurological event; and selecting a first method of treatment or a second method of treatment, wherein said first method of treatment and second method of treatment are dependent on whether said patient is likely to develop peripheral neuropathy in response to said treatment for cancer. 
ili 2 kopije rjeđeg alela, T, od rs1261134, pri čemu prisutnost navedenog biomarkera ukazuje na povećani rizik za nastanak spomenutog štetnog neurološkog događaja; i odabir prvog postupka liječenja ili odabir drugog postupka liječenja, pri čemu su navedeni prvi postupak liječenja i drugi postupak liječenja ovisni o tome da li je vjerojatno da će navedeni pacijent razviti perifernu neuropatiju kao odgovor na navedeni tretman raka.
The method of claim 7, wherein said first method of treatment comprises treating said patient with an agent that provides a physiological effect directed against said cancer without modification for peripheral neuropathy. 
Postupak prema zahtjevu 7, naznačen time da navedeni prvi postupak liječenja sadrži liječenje navedenog pacijenta sa sredstvom koje pruža fiziološki učinak usmjeren protiv navedenog raka bez izmjena za perifernu neuropatiju.
The method of claim 8, wherein said second method of treatment comprises treating said patient with an agent that provides a physiological effect directed against said cancer with modification for peripheral neuropathy. 
Postupak prema zahtjevu 8, naznačen time da navedeni drugi postupak liječenja sadrži liječenje navedenog pacijenta sa sredstvom koje pruža fiziološki učinak usmjeren protiv navedenog raka sa izmjenom za perifernu neuropatiju.
A method for selecting a patient for administration of a method of treatment for cancer, wherein said cancer treatment comprises administration of a proteasome inhibitor, wherein said method comprises: comparing a presence or absence of at least one biomarker selected from the group consisting of the homozygous genotype of the minor allele, G, of the sequence variance rs4553808; 
Postupak za odabir pacijenta za primjenu postupka liječenja raka, naznačen time da se navedeno liječenje raka sastoji od davanja inhibitora proteazoma, pri čemu navedeni postupak sadrži: usporedbu postojanja ili nepostojanja barem jednog biomarkera odabranog iz skupine koju čine homozigotan genotip rjeđeg alela, G, varijance sekvence rs4553808;
A composition for siRNA delivery, comprising a siRNA, and a carrier composition for siRNA delivery, comprising (A) a diacylphosphatidylcholine, (B) at least one member selected from the group consisting of cholesterol and cationic lipids having a cholesterol skeleton, and (C) an aliphatic primary amine. 
Sastav za isporuku siRNK, koji sadrži siRNK i sastav nosača za isporuku siRNK, naznačen time, da obuhvaća (A) diacilfosfatidilkolin, (B) najmanje jedan član odabran iz skupine koju čine kolesterol i kationski lipidi koji imaju kolesterolski kostur, i (C) alifatski primarni amin.
The composition for siRNA delivery according to Claim 1, wherein the component (A) is a diacylphosphatidylcholine whose acyl group moiety has 4 to 23 carbon atoms. 
Sastav za isporuku siRNK prema zahtjevu 1, naznačen time, da sastojak (A) je diacilfosfatidilkolin čiji dio acilne skupine ima 4 do 23 atoma ugljika.
The composition for siRNA delivery according to Claim 1 or 2, wherein the component (B) is cholesterol. 
Sastav za isporuku siRNK prema zahtjevu 1 ili 2, naznačen time, da sastojak (B) je kolesterol.
The composition for siRNA delivery according to any one of Claims 1-3, wherein the component (C) is an alkylamine having 10 to 20 carbon atoms. 
Sastav za isporuku siRNK prema bilo kojem od zahtjeva 1 do 3, naznačen time, da sastojak (C) je alkilamin koji ima 10 do 20 atoma ugljika.